Drugs / LGT209
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01859455 | Jul 2011 → Jul 2012 | hyperlipidemia, low density lipoprotein cholesterol, mild elevation of | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01979601 | Dec 2010 → Nov 2011 | hyperlipoproteinemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LGT209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01979601 ↗ |
| Route | Subcutaneous | “50 mg LGT209 subcutaneous (SC) (1 mL injection x 1 site) in statin patients” NCT01859455 ↗ |